In murine models, mesothelin-targeted CAR T-cells demonstrated robust tumor eradication, especially when combined with lymphodepleting chemotherapy or engineered to co-express immune stimulatory molecules such as interleukin-12 (IL-12) or dominant-negative TGF-β receptors to enhance CAR T-cell function within the hostile pancreatic TME [123,124,125]. The gene discussed is MSLN; the disease is neoplasm.